Zydus Cadila has received final approval from the USFDA to market Atazanavir Capsules (US RLD: ReyatazTM Capsules) in the strengths of 150 mg, 200 mg, and 300 mg.
Atazanavir, an antiretroviral drug, is used to treat infection of the Human Immunodeficiency Virus (HIV).
It is used in combination with other antiretroviral drugs to treat HIV-1 infection.
The drug will be manufactured at the group’s manufacturing facility at SEZ, Ahmedabad.
The group now has 291 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Cadila is a global pharmaceutical company headquartered in Ahmedabad, India. The company discovers, develops, manufactures, and markets a broad range of healthcare therapies.
The group has manufacturing sites and research facilities spread across five states of Gujarat, Maharashtra, Goa, Himachal Pradesh and Sikkim in India and in the US and Brazil.
